DIGOXIN INJECTION C.S.D. LIQUID

Country: Kanada

Tungumál: enska

Heimild: Health Canada

Virkt innihaldsefni:

DIGOXIN

Fáanlegur frá:

SANDOZ CANADA INCORPORATED

ATC númer:

C01AA05

INN (Alþjóðlegt nafn):

DIGOXIN

Skammtar:

0.5MG

Lyfjaform:

LIQUID

Samsetning:

DIGOXIN 0.5MG

Stjórnsýsluleið:

INTRAMUSCULAR

Einingar í pakka:

10X2ML

Gerð lyfseðils:

Prescription

Lækningarsvæði:

CARDIOTONIC AGENTS

Vörulýsing:

Active ingredient group (AIG) number: 0107281002; AHFS:

Leyfisstaða:

APPROVED

Leyfisdagur:

2005-10-05

Vara einkenni

<
D
IGOXIN INJECTION
C.S.D.
>
Page 1 of 42
Product Monograph
INCLUDING PATIENT MEDICATION INFORMATION
Pr
DIGOXIN INJECTION C.S.D.
Digoxin Injection
Liquid, 0.5 mg / 2 mL, Intramuscular, Intravenous
Manufacturer’s Standard
Cardiotonic Glycoside
Sandoz Canada Inc.
110 rue de Lauzon
Boucherville, QC, Canada
J4B 1E6
Date of Initial Authorization:
DEC 31, 1994
Date of Revision:
SEP 14, 2022
Submission Control Number: 262879
_ _
_ _
Page 2 of 42
RECENT MAJOR LABEL CHANGES
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics (<10 years of age)
................................................................................
4
1.2
Geriatrics (>70 years of age)
................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
4
DOSAGE AND ADMINISTRATION
.................................................................................
5
4.1
Dosing Considerations
.........................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
.................................................... 5
4.4
Administration
...................................................................................................
10
4.5
Missed Dose
..........................................................................................